Literature DB >> 21470834

The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397).

G C Barnett1, G De Meerleer, S L Gulliford, M R Sydes, R M Elliott, D P Dearnaley.   

Abstract

AIMS: A variety of dosimetric parameters have been shown to influence the incidence of late radiation toxicity. The effect of other treatment- and patient-related factors is less well established. The aim of this study was to elucidate the influence of such factors in the development of late symptoms after radical radiotherapy to the prostate.
MATERIALS AND METHODS: Patient- and treatment-related factors that are thought to influence the development of late toxicity were analysed in 788 patients who had received radical radiotherapy to the prostate in the Medical Research Council RT01 trial. Late toxicity data were recorded using the Radiation Therapy Oncology Group, Late Effects of Normal Tissues/Subjective, Objective, Management, Analytic, Royal Marsden Hospital and the University of California, Los Angeles, Prostate Cancer Index. Acute toxicity was measured using the Radiation Therapy Oncology Group grading system.
RESULTS: On multivariate analysis, acute bowel toxicity was statistically significantly associated with increased proctitis (hazard ratio=1.63, 95% confidence interval 1.18, 2.24; P=0.003) and increased stool frequency (hazard ratio=1.77, 95% confidence interval 1.27, 2.46; P=0.001). Hypertension was strongly associated with a decreased risk of poor urinary stream (hazard ratio=0.25, 95% confidence interval 0.09, 0.71; P=0.009). There was an increased risk of rectal bleeding with increased age (hazard ratio=1.04 per year of age, 95% confidence interval 1.01, 1.08; P=0.009). As expected, a higher prescribed dose increased the risk of several late toxicity end points. Although acute bladder toxicity was associated with the presence of bladder symptoms at 5 years, the effect disappeared for all symptoms except increased urinary frequency and haematuria when a change in bladder function from baseline was calculated. Patients with any pretreatment bladder symptoms were more likely to report increased urinary frequency (hazard ratio=2.09, 95% confidence interval 1.48, 2.95; P<0.0005), increased urinary incontinence (hazard ratio=4.22, 95% confidence interval 2.13, 8.35; P<0.0005) and decreased stream (hazard ratio=2.64, 95% confidence interval 1.62, 4.31; P<0.0005), after treatment and before the most recent follow-up assessment.
CONCLUSIONS: In this study, increased acute gastrointestinal and bladder symptoms and prescribed dose were associated with increased late radiation toxicity. The presence of hypertension seemed to be protective for the development of late effects. Baseline symptoms should be taken into account when radiation toxicity is analysed.
Copyright © 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21470834     DOI: 10.1016/j.clon.2011.03.001

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  24 in total

Review 1.  Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.

Authors:  Sarah L Kerns; Harry Ostrer; Barry S Rosenstein
Journal:  Cancer Discov       Date:  2014-01-17       Impact factor: 39.397

2.  Radioprotective effect of calcium channel blockers against late rectal bleeding in prostate cancer.

Authors:  Mariangela Massaccesi; Edy Ippolito; Francesco Deodato; Savino Cilla; Cinzia Digesù; Gabriella Macchia; Luciana Caravatta; Vincenzo Picardi; Gian Carlo Mattiucci; Alessandra Di Lallo; Daniele Cuscunà; Numa Cellini; Vincenzo Valentini; Alessio G Morganti
Journal:  Radiol Med       Date:  2013-12-06       Impact factor: 3.469

Review 3.  Strategic evaluation of interventions to prevent consequential late proctitis after prostate radiation therapy: new clinical trial designs should be considered.

Authors:  Timothy N Showalter; Nolan A Wages; Nitin Ohri
Journal:  Cancer Biol Ther       Date:  2014-02-04       Impact factor: 4.742

4.  Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.

Authors:  Sarah L Kerns; Richard G Stock; Nelson N Stone; Seth R Blacksburg; Lynda Rath; Ana Vega; Laura Fachal; Antonio Gómez-Caamaño; Dirk De Ruysscher; Guido Lammering; Matthew Parliament; Michael Blackshaw; Michael Sia; Jamie Cesaretti; Mitchell Terk; Rosetta Hixson; Barry S Rosenstein; Harry Ostrer
Journal:  Radiother Oncol       Date:  2013-05-26       Impact factor: 6.280

Review 5.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

6.  Predictive Factors of Late-onset Rectal Mucosal Changes After Radiotherapy of Prostate Cancer.

Authors:  Edy Ippolito; Alessandra Guido; Gabriella Macchia; Francesco Deodato; Lucia Giaccherini; Andrea Farioli; Alessandra Arcelli; Dajana Cuicchi; Leonardo Frazzoni; Savino Cilla; Milly Buwenge; Giovanna Mantini; Anna R Alitto; Marianna Nuzzo; Vincenzo Valentini; Marcello Ingrosso; Alessio G Morganti; Lorenzo Fuccio
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

Review 7.  Non-surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis.

Authors:  Fleur T van de Wetering; Leen Verleye; H Jervoise N Andreyev; Jane Maher; Joan Vlayen; Bradley R Pieters; Geertjan van Tienhoven; Rob J P M Scholten
Journal:  Cochrane Database Syst Rev       Date:  2016-04-25

8.  Why we should take care of the competing risk bias in survival analysis: A phase II trial on the toxicity profile of radiotherapy for prostate cancer.

Authors:  Annarita Tullio; Alessandro Magli; Eugenia Moretti; Francesca Valent
Journal:  Rep Pract Oncol Radiother       Date:  2019-08-19

9.  Volumetric image-guided conformal radiotherapy for localized prostate cancer: Analysis of dosimetric and clinical factors affecting acute and late toxicity.

Authors:  Gianluca Ingrosso; Alessandra Carosi; Daniela di Cristino; Elisabetta Ponti; Andrea Lancia; Marta Bottero; Alessandro Cancelli; Alessandra Murgia; Irene Turturici; Riccardo Santoni
Journal:  Rep Pract Oncol Radiother       Date:  2018-08-13

10.  A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.

Authors:  Laura Fachal; Antonio Gómez-Caamaño; Gillian C Barnett; Paula Peleteiro; Ana M Carballo; Patricia Calvo-Crespo; Sarah L Kerns; Manuel Sánchez-García; Ramón Lobato-Busto; Leila Dorling; Rebecca M Elliott; David P Dearnaley; Matthew R Sydes; Emma Hall; Neil G Burnet; Ángel Carracedo; Barry S Rosenstein; Catharine M L West; Alison M Dunning; Ana Vega
Journal:  Nat Genet       Date:  2014-06-29       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.